Imugene Stock Beta
| IMU Stock | 0.04 0 2.56% |
Imugene fundamentals help investors to digest information that contributes to Imugene's financial success or failures. It also enables traders to predict the movement of Imugene Stock. The fundamental analysis module provides a way to measure Imugene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Imugene stock.
Imugene | Beta |
Imugene Company Beta Analysis
Imugene's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Imugene Beta | 3.34 |
Most of Imugene's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Imugene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Imugene has a Beta of 3.34. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The beta for all Australia stocks is notably lower than that of the firm.
Imugene Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Imugene's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Imugene could also be used in its relative valuation, which is a method of valuing Imugene by comparing valuation metrics of similar companies.Imugene is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Imugene will likely underperform.
Imugene Fundamentals
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | 22.86 % | ||||
| Current Valuation | 195.99 M | ||||
| Shares Outstanding | 7.57 B | ||||
| Shares Owned By Insiders | 14.38 % | ||||
| Shares Owned By Institutions | 6.60 % | ||||
| Price To Book | 2.43 X | ||||
| Price To Sales | 59.38 X | ||||
| Revenue | 4.97 M | ||||
| Gross Profit | 11.78 M | ||||
| EBITDA | (147.98 M) | ||||
| Net Income | (149.68 M) | ||||
| Cash And Equivalents | 49.54 M | ||||
| Total Debt | 1.55 M | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (97.32 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Target Price | 0.3 | ||||
| Beta | 3.34 | ||||
| Market Capitalization | 295.12 M | ||||
| Total Asset | 151.4 M | ||||
| Retained Earnings | (289.83 M) | ||||
| Working Capital | 83.74 M | ||||
| Net Asset | 151.4 M |
About Imugene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Imugene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Imugene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Imugene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.